- Home
- BLRX vs LGVN Comparison
BLRX vs LGVN Comparison
Compare BLRX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- LGVN
- Stock Information
- Founded
- BLRX 2003
- LGVN 2014
- Country
- BLRX Israel
- LGVN United States
- Employees
- BLRX N/A
- LGVN N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BLRX Health Care
- LGVN Health Care
- Exchange
- BLRX Nasdaq
- LGVN Nasdaq
- Market Cap
- BLRX 17.2M
- LGVN 16.4M
- IPO Year
- BLRX 2011
- LGVN 2021
- Fundamental
- Price
- BLRX $3.81
- LGVN $0.75
- Analyst Decision
- BLRX Strong Buy
- LGVN Strong Buy
- Analyst Count
- BLRX 2
- LGVN 2
- Target Price
- BLRX $19.00
- LGVN $6.50
- AVG Volume (30 Days)
- BLRX 32.7K
- LGVN 416.4K
- Earning Date
- BLRX 08-14-2025
- LGVN 11-11-2025
- Dividend Yield
- BLRX N/A
- LGVN N/A
- EPS Growth
- BLRX N/A
- LGVN N/A
- EPS
- BLRX N/A
- LGVN N/A
- Revenue
- BLRX $17,251,000.00
- LGVN $2,073,000.00
- Revenue This Year
- BLRX N/A
- LGVN N/A
- Revenue Next Year
- BLRX N/A
- LGVN N/A
- P/E Ratio
- BLRX N/A
- LGVN N/A
- Revenue Growth
- BLRX 1.19
- LGVN 68.67
- 52 Week Low
- BLRX $2.30
- LGVN $0.63
- 52 Week High
- BLRX $26.80
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- BLRX 49.18
- LGVN 35.26
- Support Level
- BLRX $3.68
- LGVN $0.74
- Resistance Level
- BLRX $4.11
- LGVN $0.85
- Average True Range (ATR)
- BLRX 0.24
- LGVN 0.05
- MACD
- BLRX 0.02
- LGVN 0.02
- Stochastic Oscillator
- BLRX 41.50
- LGVN 18.84
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.